Balant L P, Balant-Gorgia A E, Eisele R, Reith B, Gex-Fabry M, Garrone G
Department of Psychiatry, University of Geneva, Switzerland.
Pharmacopsychiatry. 1989 Nov;22(6):250-4. doi: 10.1055/s-2007-1014609.
The purpose of the present study was to evaluate zuclopenthixol acetate in Viscoleo, a new preparation to be administered once every 3 days, in the early treatment of acute psychotic episodes and acute deterioration of chronic psychosis. 21 cases were included in the study: patients received 1 to 3 injections. Clinical evaluation was made at 24, 48 and 72 hours after each injection, using the Clinical Global Impressions (CGI) and the Brief Psychiatric Rating Scale (BPRS). Results at end-point indicated a marked or moderate therapeutic effect in the 11 cases of acute psychosis. A statistically significant decrease was observed for the total BPRS score as well as for its subscales. Among 8 cases of exacerbation of chronic psychosis, 4 patients showed a moderate therapeutic effect, and minimal or no effect was found in the other 4 subjects. The total BPRS decreased significantly, but to a lesser extent than for acute psychosis. Two patients suffering from mania showed a moderate therapeutic effect according to CGI. 8 cases of acute psychosis and 5 cases of chronic psychosis did not suffer from any neurological side-effects. Plasma concentration measurements suggest that a dose of 50 mg per 3 days may be sufficient for early treatment of most acutely ill psychotic patients.
本研究的目的是评估醋酸珠氯噻醇油剂（一种每3天给药一次的新制剂）在急性精神病发作和慢性精神病急性恶化的早期治疗中的效果。21例患者纳入研究：患者接受1至3次注射。每次注射后24、48和72小时进行临床评估，采用临床总体印象量表（CGI）和简明精神病评定量表（BPRS）。终点结果显示，11例急性精神病患者有显著或中度治疗效果。BPRS总分及其各子量表得分均有统计学意义的下降。在8例慢性精神病急性加重患者中，4例有中度治疗效果，另外4例效果轻微或无效果。BPRS总分显著下降，但幅度小于急性精神病患者。根据CGI，2例躁狂患者有中度治疗效果。8例急性精神病患者和5例慢性精神病患者未出现任何神经副作用。血浆浓度测量结果表明，每3天50mg的剂量可能足以早期治疗大多数急性精神病患者。
